secwatch.observer — SEC 8-K summary
======================================

Issuer:     Barinthus Biotherapeutics plc. (BRNS)
CIK:        0001828185
Form:       8-K
Filed at:   2025-01-10T23:59:59+00:00
Accession:  0001828185-25-000004
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 2.05, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Barinthus Bio restructures: cuts 65% workforce, shifts focus to celiac VTP-1000
-------------------------------------------------------------------------------

- Workforce reduction of ~65%; plans to close UK site, consolidate operations in Germantown, MD.
- CFO Gemma Brown (departing April 30, 2025) and COO Graham Griffiths (June 30, 2025) to leave; severance agreements anticipated.
- Prioritizes VTP-1000 (celiac disease) with Phase 1 data expected mid-2025; postpones VTP-300 hepatitis B development until partner found.
- Preliminary cash, cash equivalents and restricted cash of $112M as of Dec 31, 2024; cash runway extended to start 2027.
- Key 2025 milestones: VTP-1000 SAD data mid-2025; HBV003 and IM-PROVE II results in Q2 2025; VTP-850 prostate cancer data Q2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828185/000182818525000004/0001828185-25-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828185/000182818525000004/brns-20250110.htm
  HTML page:      https://secwatch.observer/filing/0001828185-25-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer